So basically you're admitting that alienating NN, one of the...

So basically you're admitting that alienating NN, one of the biggest drug companies in the world, was the wrong thing to do?

NN could easily have the infrastructure already in place to conduct the trials needed to ascertain chp10s viability as a drug in the arthiritus or lupus market.

Goran Ando stayed on the board after the initial results, I should mention Goran will be chairman of NN next year.

He only left after the revolt of the board, several months later.

Now it is fair to say, someone of Goran's status, is a busy guy and wouldn't waist time on the board of a company with a dud drug.

To me, this new direction from the company is nothing but a boards attempt to show they have made progress. Progress doesnt mean that it will materially bring us closer to a commercialised product.

We need someone on this board who has strong relationships with the people who make this dream a reality.

I have 10s of thousands of dolars in this company, my only motivation is we get what we could of gotten.

My opinion, but I actually do my research thoroughly and have been in business long enough to know what works and how the world works.